Binding of STAT3 with VHH13 generated in bacteria and VHH14 derived from mammalian source. (A) Schematic comparison of conventional antibodies and small-molecular-weight camelid antibodies devoid of light chain comprising heavy chain with variable region (VHH). (B) The kinetics profiles of bacterial VHH13-human STAT3. Binding of human STAT3 with anti-STAT3 B VHH was determined using Biacore 3000. For scouting, the sample was allowed to flow over the chip and the binding of sample to the ligand was monitored in real time. The affinity constant (KD) was determined as a ratio of dissociation and association rates. (C) Western blot showing the immunoprecipitation of various STAT3 VHHs to MDA-MB-231 cells using Dynabeads coupled with STAT3 VHHs, commercially available STAT3 was used as a positive control, and STAT1 as a negative control. The band densities were determined using UN-SCAN-IT software (Silk Scientific Inc., Orem, UT, USA). (D) Comparative expression of STAT3 in breast (MDA-MB-231, 4T1), pancreatic (Panc-1), and prostate (DU145) cancer cells and HeLa cells. Western blot showing the immunoprecipitation of bacterial STAT3 VHH13 to cell lysates from breast, pancreatic and prostate cancer cells as well as HeLa + IFN-γ. For this, cell lysate was incubated with Dynabeads coupled with STAT3 VHH13.